Trial record 1 of 1 for:    belviq phentermine
Previous Study | Return to List | Next Study

A Multicenter Pilot Study of 12-week Duration to Assess the Short-term Safety and Tolerability of Lorcaserin Plus Two Doses of Immediate- Release Phentermine-HCl Compared With Lorcaserin Alone in Overweight and Obese Adults

This study is ongoing, but not recruiting participants.
Sponsor:
Information provided by (Responsible Party):
Eisai Inc.
ClinicalTrials.gov Identifier:
NCT01987427
First received: November 12, 2013
Last updated: May 5, 2014
Last verified: May 2014
  Purpose

APD356-A001-402 is a multicenter, double-blind, randomized, parallel-group pilot study of 12-week duration in overweight and obese adults. Approximately 225 subjects will be randomized to one of three treatment arms in a ratio 1:1:1 and will receive the combinations of lorcaserin 10 mg twice daily (BID) plus immediate-release phentermine-HCl 15 mg BID or 15 mg once daily (QD), or lorcaserin alone.


Condition Intervention Phase
Chronic Weight Management
Drug: lorcaserin
Drug: phentermine-HCl
Drug: phentermine placebo BID
Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Investigator)
Primary Purpose: Treatment
Official Title: A Multicenter Pilot Study of 12-week Duration to Assess the Short-term Safety and Tolerability of Lorcaserin Plus Two Doses of Immediate- Release Phentermine-HCl Compared With Lorcaserin Alone in Overweight and Obese Adults

Resource links provided by NLM:


Further study details as provided by Eisai Inc.:

Primary Outcome Measures:
  • Proportion of subjects reporting at least one of nine common serotonergic adverse events (AEs) from baseline to Week 12/End of Treatment (EOT). [ Time Frame: Up to 12 Weeks ] [ Designated as safety issue: Yes ]
    Common serotonergic adverse events include: headache, dizziness, nausea, fatigue, dry mouth, diarrhea, vomiting, insomnia, and/or anxiety


Secondary Outcome Measures:
  • Incidence rates of Treatment Emergent Aes (TEAEs), Serious AE (SAEs), and AEs leading to discontinuation/withdrawal; laboratory result values [ Time Frame: Baseline and Week 12 ] [ Designated as safety issue: Yes ]
  • Relationship between exposure to lorcaserin and phentermine and response, as determined by change from baseline in body weight (kg and %) and occurrence of most frequently occurring AEs [ Time Frame: Up to 12 Weeks ] [ Designated as safety issue: Yes ]
  • Change from baseline in body weight (kg and %) at Week 12 and intermediate time points [ Time Frame: Baseline and Week 12 ] [ Designated as safety issue: No ]
  • Proportion of subjects achieving greater than or equal to 5% weight reduction at Week 12/EOT [ Time Frame: Baseline and Week 12 ] [ Designated as safety issue: No ]
  • Change from baseline in waist circumference, hip circumference, and waist/hip ratio at Week 12/EOT. [ Time Frame: Baseline and Week 12 ] [ Designated as safety issue: No ]

Estimated Enrollment: 225
Study Start Date: October 2013
Estimated Study Completion Date: July 2014
Estimated Primary Completion Date: July 2014 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: A
lorcaserin 10 mg BID + phentermine placebo BID
Drug: lorcaserin
lorcaserin 10 mg
Drug: phentermine placebo BID
phentermine placebo
Experimental: B
lorcaserin 10 mg BID + phentermine-HCl 15 mg QD + phentermine placebo QD
Drug: lorcaserin
lorcaserin 10 mg
Drug: phentermine-HCl
phentermine-HCl 15 mg
Drug: phentermine placebo BID
phentermine placebo
Experimental: C
lorcaserin 10 mg BID + phentermine-HCl 15 mg BID
Drug: lorcaserin
lorcaserin 10 mg
Drug: phentermine-HCl
phentermine-HCl 15 mg
Drug: phentermine placebo BID
phentermine placebo

Detailed Description:

All subjects will take lorcaserin and phentermine-HCl/placebo once in the morning and again in the mid-afternoon. The dosing is timed to help reduce potential insomnia due to phentermine. Subjects in Arm A will take one tablet twice daily of lorcaserin 10 mg in combination with one capsule twice daily of phentermine placebo. Subjects in Arm B will take one tablet twice daily of lorcaserin 10 mg, one capsule of phentermine-HCl 15 mg once daily in the morning, and one capsule of phentermine placebo once daily in the mid-afternoon. Subjects in Arm C will take one tablet twice daily of lorcaserin 10 mg in combination with one capsule twice daily of phentermine-HCl 15 mg. Subjects will be instructed to take lorcaserin tablets and phentermine/placebo capsules concurrently and attempt to remain on a consistent daily schedule. The study will recruit obese (body mass index [BMI] greater than or equal to 30 kg/m2) subjects with or without a weight-related comorbid condition (e.g., hypertension, dyslipidemia, or sleep apnea) or overweight (BMI greater than or equal to 27 to 29.9 kg/m2) subjects with at least one weight-related co-morbid condition. At least one third of the subjects will have a BMI of 40 kg/m2 or greater, because there is a high likelihood that this combination therapy will be used by these subjects in medical practice.

A lifestyle intervention program, using a 12-week adaptation of the Arena Healthy Lifestyles Program, including diet and exercise counseling, will be implemented for obesity/overweight.

Blood sampling will be performed to evaluate the pharmacokinetics (PK) of lorcaserin and phentermine using population PK modeling as well as the potential relationships between exposure to the lorcaserin/phentermine and measures of safety and change from baseline in body weight, using population PK/PD (pharmacodynamics) modeling.

  Eligibility

Ages Eligible for Study:   18 Years to 60 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria

  1. BMI is 30 kg/m2 or greater with or without a weight-related comorbid condition (e.g., hypertension, dyslipidemia, sleep apnea), or 27 to 29.9 kg/m2 with at least one weight-related comorbid condition.
  2. Ambulatory and able to perform moderate exercise.
  3. Male or female subjects between 18 and 60 years at the time of informed consent.
  4. Provide written informed consent.
  5. Willing and able to comply with all aspects of the protocol.

Exclusion Criteria

  1. Recent treatment (within 14 days of the Screening Visit and any time prior to randomization) with monoamine oxidase inhibitors (MAOIs). MAOIs have been associated with a risk of hypertensive crisis when used with phentermine.
  2. Active or recent history (within 1 month prior to the Screening Visit) of major depression or other major psychiatric disease requiring treatment (i.e., within 1 month of the Screening Visit and any time prior to randomization or thereafter during the study) with prescription medication (e.g., SSRIs, SNRIs, tricyclics, antipsychotics, lithium, Wellbutrin).
  3. Use of selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs) (including bupropion) for reasons other than active psychiatric indications (e.g., migraine, weight loss, smoking cessation) within 1 month prior to the Screening Visit).
  4. Medication history that includes use of one or more of the following:

    1. Fenfluramine or related derivatives (i.e., dexfenfluramine, norfenfluramine)
    2. Agents that have documented correlation with increased incidence of valvulopathy and/or primary pulmonary hypertension (e.g., cabergoline, cyproheptadine, trazodone, nefazodone, amoxapine, mirtazapine, pergolide, ergotamine, methysergide)
  5. Recent treatment (i.e., within 1 month of the Screening Visit and any time prior to randomization or thereafter during the study) with over-the-counter (OTC) weight loss products or appetite suppressants (including herbal weight loss agents), or within 6 months and any time prior to randomization or thereafter during the study, with a prescription weight loss drug (e.g., phentermine, phentermine/topiramate, orlistat).
  6. Use of St. John's Wort within 1 month prior to the Screening Visit and for the duration of the study. St. John's Wort has been associated with serotonin syndrome when used with another serotonergic drug.
  7. Hypersensitivity to sympathomimetic amines or the study drugs.
  8. History of stroke, transient ischemic attack, arrhythmias, congestive heart failure, and/or peripheral vascular disease.
  9. Recent history of active cardiovascular disease, including chronic stable angina or an unstable angina episode or myocardial infarction within the 3 months prior to the Screening Visit.
  10. Uncontrolled hypertension defined as systolic blood pressure greater than or equal to 150 or diastolic blood pressure greater than or equal to 95 on 2 readings taken on different days. Subjects who have uncontrolled hypertension at screening may be re-screened greater than 1 month following initiation or adjustment of antihypertensive therapy.
  11. History of or active pulmonary artery hypertension.
  12. Severe renal impairment (creatinine clearance less than 30 mL/min, as calculated by the Cockroft-Gault equation based on ideal body weight) or end stage renal disease.
  13. History of valve replacement surgery; clinically significant valvular stenosis; history of or active clinically significant valvulopathy (defined as aortic insufficiency of mild, moderate, or severe intensity and/or mitral insufficiency of moderate or severe intensity).
  14. History of or active (confirmed fasting glucose greater than 126 mg/dL or hemoglobin A1c [HbA1c] greater than ULN [6.5% at central laboratory]) diabetes mellitus (type I, II or other) and/or currently taking medications for type I or II diabetes. A past history of gestational diabetes that has resolved is permissible.
  15. Glaucoma.
  16. Abnormal thyroid stimulating hormone (TSH) laboratory value greater than 1.5 x Upper Limit of Normal (ULN)
  17. Hyperthyroidism, including abnormal screening laboratory values with T3 greater than ULN and TSH less than Lower Limit of Normal (LLN), and subjects taking methimazole or propylthiouracil (PTU) and/or beta-blockers for hyperthyroidism.
  18. Recent history (within 2 years prior to the Screening Visit) of alcohol or drug/solvent abuse or a positive screen for drugs of abuse at screening.
  19. Significant change is smoking habits or tobacco product use within 3 months prior to the Screening Visit.
  20. Use of tobacco products (i.e., smokes more than one-half pack of cigarettes per day, or smokes more than 2 cigars per day, or uses 3 or more pinches of smokeless tobacco per day).
  21. Surgical procedure for the treatment of obesity (i.e., gastric bypass, gastric banding), even if reversed prior to screening.
  22. Planned surgery during the study period that may interfere with completion or compliance with the protocol.
  23. A prolonged QT/QTc interval (QTc Bazett's greater than 450 msec) as demonstrated by a repeated electrocardiogram (ECG).
  24. Participation in any clinical study with an investigational drug, biologic, or device within 1 month prior to screening.
  25. Significant change in diet or level of physical activity within 1 month prior to dosing that in the opinion of the investigator(s) may confound the results of the study.
  26. Change in weight of greater than 5 kg within 3 months of screening.
  27. Use of a very-low calorie (less than 800/day) liquid weight loss diet within 6 months prior to screening and any time prior to randomization.
  28. Eligible male and female subjects participating in a conception process (i.e., active attempt to become pregnant or to impregnate, sperm donation, in vitro fertilization).
  29. Females who are lactating or pregnant at Screening or Baseline Visit (as documented by a negative serum or urine pregnancy test with a minimum sensitivity of 25 IU/L or equivalent units of beta-human chorionic gonadotropin [B-hCG]). A separate baseline assessment is required if a negative screening pregnancy test was obtained more than 72 hours before the first dose of study drug.
  30. All females will be considered to be of childbearing potential unless they are postmenopausal (amenorrheic for at least 12 consecutive months, in the appropriate age group and without other known or suspected cause) or have been sterilized surgically (i.e., bilateral tubal ligation, total hysterectomy, or bilateral oophorectomy, all with surgery at least one month before dosing).
  31. Females of childbearing potential must not have had unprotected sexual intercourse within 30 days before study entry and must agree to use a highly effective method of contraception (e.g., total abstinence, an intrauterine device, a double-barrier method [such as condom plus diaphragm with spermicide], a contraceptive implant, an oral contraceptive, or have a vasectomized partner with confirmed azoospermia) throughout the entire study period and for 30 days after study drug discontinuation. If currently abstinent, the subject must agree to use a double barrier method as described above if she becomes sexually active during the study period or for 30 days after study drug discontinuation. Females who are using hormonal contraceptives must have been on a stable dose of the same hormonal contraceptive product for at least 4 weeks before dosing and must continue to use the same contraceptive during the study and for 30 days after study drug discontinuation. Females not meeting these criteria will be excluded from the study.
  32. Any medical or other condition that in the opinion of the investigator(s) would preclude the subject's participation in a clinical study, such as significantly abnormal laboratory results or any physical or mental condition that prevents compliance with the protocol.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01987427

Locations
United States, Alabama
University of Alabama at Birmingham
Birmingham, Alabama, United States, 35294
United States, Arizona
Radiant Research - Arizona
Chandler, Arizona, United States, 85224
United States, California
Scripps Clinical Research Center
La Jolla, California, United States, 92037
United States, Florida
Translational Research Institute for Metabolism and Diabetes
Orlando, Florida, United States, 32804
United States, Louisiana
Pennington Biomedical Research Center
Baton Rouge, Louisiana, United States, 70808
United States, Massachusetts
Boston Medical Center
Boston, Massachusetts, United States
United States, New York
Weill Cornell College
New York, New York, United States, 10065
United States, North Carolina
Duke University
Durham, North Carolina, United States, 27710
United States, Ohio
Radiant Research - Columbus
Columbus, Ohio, United States, 43212
United States, South Carolina
Radiant Research - South Carolina
Anderson, South Carolina, United States, 29621
United States, Texas
Radiant Research - Dallas
Dallas, Texas, United States, 75231
United States, Virginia
National Clinical Research - Norfolk
Norfolk, Virginia, United States, 23502
National Clinical Research - Richmond
Richmond, Virginia, United States, 23294
Sponsors and Collaborators
Eisai Inc.
  More Information

No publications provided

Responsible Party: Eisai Inc.
ClinicalTrials.gov Identifier: NCT01987427     History of Changes
Other Study ID Numbers: APD356-A001-402
Study First Received: November 12, 2013
Last Updated: May 5, 2014
Health Authority: United States: Food and Drug Administration

Keywords provided by Eisai Inc.:
Overweight
Obese
Weight Management

Additional relevant MeSH terms:
Phentermine
Overweight
Body Weight
Signs and Symptoms
Central Nervous System Stimulants
Physiological Effects of Drugs
Pharmacologic Actions
Central Nervous System Agents
Therapeutic Uses
Appetite Depressants
Anti-Obesity Agents
Sympathomimetics
Autonomic Agents
Peripheral Nervous System Agents
Adrenergic Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action

ClinicalTrials.gov processed this record on September 18, 2014